Free tool
FAERS Monitor: Clindesse
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050793 or its brand name (Clindesse, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.
Reports
3,697
Serious
2,334
63% of reports
Hospitalization
1,091
Death reported
269
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective382
- rash260
- drug hypersensitivity230
- off label use230
- nausea196
- diarrhoea193
- pain182
- fatigue175
- pruritus174
- condition aggravated139
- headache120
- dyspnoea118
- pyrexia111
- product use in unapproved indication109
- vomiting104
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 48 |
| 2006 | 58 |
| 2007 | 14 |
| 2008 | 25 |
| 2009 | 48 |
| 2010 | 86 |
| 2011 | 75 |
| 2012 | 102 |
| 2013 | 110 |
| 2014 | 107 |
| 2015 | 131 |
| 2016 | 247 |
| 2017 | 216 |
| 2018 | 243 |
| 2019 | 294 |
| 2020 | 214 |
| 2021 | 197 |
| 2022 | 297 |
| 2023 | 306 |
| 2024 | 286 |
| 2025 | 310 |
| 2026 | 264 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,462 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 230 | 6.8 | 6.0 | 1,134 |
| rashSignal | 260 | 3.4 | 3.0 | 446 |
| condition aggravatedSignal | 139 | 2.6 | 2.2 | 137 |
| pruritusSignal | 174 | 2.6 | 2.2 | 169 |
| product use in unapproved indicationSignal | 109 | 2.5 | 2.1 | 98 |
| pyrexia | 111 | 1.8 | 1.5 | 41 |
| diarrhoea | 193 | 1.7 | 1.5 | 57 |
| pain | 182 | 1.7 | 1.5 | 52 |
| drug ineffective | 382 | 1.6 | 1.5 | 103 |
| off label use | 230 | 1.5 | 1.3 | 39 |
| nausea | 196 | 1.4 | 1.2 | 24 |
| fatigue | 175 | 1.3 | 1.1 | 11 |
| vomiting | 104 | 1.3 | 1.0 | 5 |
| dyspnoea | 118 | 1.2 | 1.0 | 3 |
| headache | 120 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.